An experimental approach to study the function of mitochondria in cardiomyopathy

Youn Wook Chung1 & Seok-Min Kang1,2,3,*

1Yonsei Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul 03722, 2Cardiology Division, Severance Cardiovascular Hospital, Seoul 03722, 3Severance Integrative Research Institute for Cerebral and Cardiovascular Diseases (SIRIC), Yonsei University Health System, Seoul 03722, Korea

Cardiomyopathy is an inherited or acquired disease of the myocardium, which can result in severe ventricular dysfunction. Mitochondrial dysfunction is involved in the pathological process of cardiomyopathy. Many dysfunctions in cardiac mitochondria are consequences of mutations in nuclear or mitochondrial DNA followed by alterations in transcriptional regulation, mitochondrial protein function, and mitochondrial dynamics and energetics, presenting with associated multisystem mitochondrial disorders. To ensure correct diagnosis and optimal management of mitochondrial dysfunction in cardiomyopathy caused by multiple pathogenesis, multidisciplinary approaches are required, and to integrate between clinical and basic sciences, ideal translational models are needed. In this review, we will focus on experimental models to provide insights into basic mitochondrial physiology and detailed underlying mechanisms of cardiomyopathy and current mitochondria-targeted therapies for cardiomyopathy. [BMB Reports 2015; 48(10): 541-548]

INTRODUCTION

Mitochondrial dysfunction plays a critical role in the underlying pathological process of ischemic heart disease (IHD) and cardiomyopathy (CM). As a leading cause of death worldwide, IHD (also known as coronary artery disease) is primarily caused by acute myocardial infarction (AMI). A precursor to heart failure, CM is acutely caused by myocardial ischemia and chronically by hypertension or diabetes mellitus. Mitochondrial damage occurs primarily during the reperfusion phase of ischemia/reperfusion (I/R) (3, 4). In the post-I/R heart, mitochondrial dysfunctions are due to inhibition of electron transport chain (ETC) function and oxygen (O2) consumption, mitochondrial calcium (Ca2+) overload, reactive oxygen species (ROS) generation, mitochondrial permeability transition (MPT) pore opening, loss of mitochondrial membrane potential (ΔΨm), and increased mitochondrial necrosis and apoptosis (5-7). Alteration of mitochondrial energy metabolism also plays a substantial role in IHD and CM (8). Not surprisingly, mitochondria are a potential therapeutic target for IHD and CM.

CARDIOMYOPATHY

The heart is composed mostly of the cardiac muscle, or myocardium. Severe or long-standing problems with the cardiac muscle can lead to heart failure. Inflammation of the heart is called myocarditis, whereas non-inflammatory cardiac muscle disease is known as CM, in which the myocardium becomes damaged, weakened, or stretched by various causes. Clinically, CM is divided into ischemic CM and non-ischemic CM, and in turn non-ischemic CM includes three types: dilated (DCM), hypertrophic (HCM), and restrictive (RCM) (9, 10). DCM is characterized by enlargement of the heart and dilated ventricle walls, which associated with reduced left ventricle function or systolic function. In contrast, HCM is characterized by a thickened wall of the left ventricle and/or by a thickened septum that separates the left ventricle and the right ventricle. In the condition of RCM, the walls of the ventricles become rigid, which reduces cardiac output due to diastolic dysfunction. Over the past few decades, another type of CM called mitochondrial CM has emerged and has been extensively studied. The clinical and pathological phenotype of mitochondrial CM, which is primarily found in DCM, HCM, arrhythmias and heart failure, results from abnormalities in the cardiac mitochondrial oxidative phosphorylation (OXPHOS) system, due to genetic defects (11).

MITOCHONDRIAL DEFECTS IN EXPERIMENTAL MODELS OF CARDIOMYOPATHY

Mitochondrial dysfunction plays a critical role in the pathogenesis of CM (12, 13). Among various animal models that have been established to study the process and mechanisms
involved in cardiac disease (14-16), many exhibit CM phenotypes associated with mitochondrial defects (Table 1).

**Transcriptional regulation**

As with nuclear DNA (nDNA), mitochondrial DNA (mtDNA) is subject to epigenetic modifications related to energetic capacity and disease status. When calories are limited, gene expression is suppressed due to decreased phosphorylation and acetylation of chromatin (17). Sirtuins, or the Silent Information Regulator 2 (SIR2) protein family includes 7 (Sirt1-7) nicotinamide adenine

---

**Table 1. Experimental models for cardiomyopathy with mitochondrial dysfunction**

| Modification                        | Species   | Phenotype | Mitochondrial abnormalities | Ref. |
|-------------------------------------|-----------|-----------|----------------------------|------|
| **Transcriptional regulation**      |           |           |                           |      |
| CAP<sup>+</sup> mtDNA germ-line transmission | Mouse     | DCM       | Enlarged mitochondria     | (22) |
| Tam cKO                            | Mouse     | DCM       | Respiration ↓             | (52) |
| Sirt7 KO                           | Mouse     | CM        | Acetylation of GABPβ1 ↑   | (19) |
| Ncoa6 cKO or DN1 TG                | Mouse     | DCM       | Complex II ↓              | (20) |
| **Mitochondrial protein function**  |           |           |                           |      |
| Scgd deficient (BIO 14.6)           | Hamster   | Congenital CM | S3 in IFM ↓, Ca<sup>2+</sup> overload | (31) |
| Sod2 KO                            | Mouse     | Neonatal DCM | Complex II ↓              | (73), (96) |
| Ant1 KO                            | Mouse     | HCM       | Respiration ↓, ROS ↑      | (57) |
| Nix/Bnip3 DKO                      | Mouse     | CM        | Accumulation of abnormal mitochondria | (37) |
| CryAB<sup>R120G</sup> mutation     | Mouse     | Desmin-related CM | Complex I ↓, MPT pore opening ↑, ΔΨm ↓ | (62) |
| Dystrophin-deficient (mdx)          | Mouse     | CM        | Substrate shift, O<sub>2</sub> consumption ↑, Ca<sup>2+</sup> overload | (66) |
| LTCC β2a subunit cTG               | Mouse     | HCM       | mtDNA stability ↓, Respiration ↓ | (21) |
| MutUNG1 TG                         | Mouse     | HCM       |                           |      |
| **Mitochondrial dynamics**          |           |           |                           |      |
| Dnm1<sup>Py/+</sup>                | Mouse     | CM        | ATP ↓                    | (49) |
| Mfn1/2 DKO                         | Mouse     | DCM       | Mitochondrial fragmentation ↑, Respiration ↓ | (39), (42), (43) |
| Opa1<sup>−/−</sup>                  | Mouse     | CM        | mtDNA stability ↓, Mitochondrial fragmentation ↑ | (44) |
| Mfn2 KO                            | Mouse     | DCM       | O<sub>2</sub> consumption ↓ | (40) |
| Drp1 cKO                           | Mouse     | DCM       | Mitophagy ↑, MPT pore opening ↑ | (39) |
| **Induced models**                 |           |           |                           |      |
| DOX-induced model                  | Rabbit    | CM        | ROS ↑                    | (79) |
| Pacing-induced model               | Dog       | DCM       | Complex I ↓, ROS ↑        | (72) |
| Fz-induced model                   | Turkey    | DCM       | Mitochondrial swelling ↑  | (68) |
| Autoantibodies (M2-AA)             | Rat       | DCM-like  | Mitochondrial swelling ↑  | (26) |

CAP<sup>+</sup>: chloramphenicol-resistant, mtDNA: mitochondrial DNA, Tam: mitochondrial transcription factor A (mtTFA), KO: knock out, cKO: conditional KO, Sirt7: sirtuin 7, GABPβ1: GA binding protein β1, Ncoa6: nuclear receptor coactivator 6, DN1: dominant-negative mutant containing an N-terminal LXXLL-1 motif of NCOA6, TG: transgenic, Scgd: δ-sarcoglycan, BIO 14.6: Syrian cardiomyopathic hamster, S3: state 3 (ADP-stimulated) respiration, IFM: interfibrillar mitochondria, Sod2: superoxide dismutase 2 (mitochondrial, manganese superoxide dismutase), Ant1: adenine nucleotide translocator, ROS: reactive oxygen species, DKO: double KO, CryAB: α-B-crystallin, mdx: X chromosome-linked muscular dystrophy, LTCC: L-type Ca<sup>2+</sup> channel, mut: mutant, UNG1: uracil-DNA glycosylase 1, Dnm1: dynamin-1-like, Py: Python (a mouse mutant), Mfn2: mitofusin 2, Opa1: optic atrophy 1, Drp1: dynamin-related protein 1, MPT pore: mitochondrial permeability transition pore, DOX: doxorubicin, Fz: furazolidone, M<sub>2</sub>-AA: M<sub>2</sub> muscarinic receptor, ΔΨm: mitochondrial membrane potential.
Dysfunction of mitochondrial dynamics and quality control

Binding of agonist to G protein-coupled receptor (GPCR) family triggers the dissociation of Gαq protein into Gαq and Gβγ subunits. GTP-bound Gαq (active form) activates phospholipase C (PLC) and ultimately protein kinase C (PKC). As activation of MAP kinase by Gαq has been implicated in stimulating cardiac growth, transgenically overexpressed Gαq in mouse hearts causes myocardial hypertrophy with systolic dysfunction and DCM with cardiac contractile failure at high-expression levels (32). Combined with a pressure overload model by surgical transverse aortic constriction (TAC) (33), Gαq-mediated myocardial hypertrophy model has been used by the same research group to study roles of pro-apoptotic Bcl-2 family protein Nix (also known as Bnip3L and Bnip3 in cardiac hypertrophy and apoptotic CM (34-36). Proapoptotic Nix is induced in Gαq-dependent and pressure overload hypertrophy, and cardiac-specific expression of Nix triggers apoptotic CM (34). Moreover, Bnip3/Nix DKO induces the accumulation of abnormal mitochondria and causes CM due to mitophagic dysfunction (37).

Mitochondrial dynamics, mitochondrial fission and fusion, are involved in the mechanisms of a variety of human diseases including cancer, neurodegenerative diseases, and cardiovascular diseases (38). Dorn and his associates have intensively studied the connection between mitochondrial dynamics and CM (39-44). Using genetic ablations of the pro-fission factor dynamin-related protein 1 (Drp1) and the pro-fusion factors mitofusins (Mfn1, Mfn2, and Mfn1/2) and optic atrophy 1 (Opa1), they demonstrated that mitochondrial fission and fusion dynamics plays an important role in pathophysiology of CM and heart failure (45). Mitophagy, the autophagy of mitochondria, is a selective clearance process of damaged or aged mitochondria (46, 47). Regulation of mitophagy requires two Parkinson’s disease factors: the mitochondrial kinase PINK1 (PTEN-induced putative kinase protein 1) and the cytosolic ubiquitin ligase Parkin (48). Mfn2-deficient mouse cardiomyocytes exhibited accumulation of morphologically and functionally abnormal mitochondria due to suppressed mitophagy and subsequent reduction of oxygen (O2) consumption, suggesting that the mitochondrial respiratory impairment contributes to the development of DCM (40). Interrupting mitochondrial fusion by combined Mfn1/Mfn2 ablation in adult hearts increased mitochondrial fragmentation and induced mitochondrial respiratory dysfunction, causing lethal DCM (39, 42, 43). Since the homozygous mutation is embryonic lethal, heterozygous Opal−/− mice were generated and examined. Abnormal cardiac function with reduced mtDNA stability and fragmented mitochondria was observed in aged Opal−/− mouse heart, which develops late-onset CM (44). In contrast, cardiomyocyte-specific Drp1 knock out (KO) mice showing increased cardiomyocyte mitophagy and mitochondrial permeability transition (MPT) pore opening, led to cardiomyocyte necrosis and DCM (39). A mutation in another mitochondrial fission gene Dnm1 (Dnm1Py/−) also led to CM. ATP depletion observed in
Dnm1Py/Py mouse heart possibly contributes to CM (49). These studies suggest that the cardiac mitochondrial quality control process is critical in pathophysiology of CM.

**Impaired mitochondrial metabolism**

Transcription of mtDNA is controlled by nuclear gene-encoded regulatory proteins such as mitochondrial transcription factor A (Tfam), also known as mtTFA (50, 51). Mutant animals, whose Tfam gene is disrupted in heart and muscle, developed DCM similar to Kearns-Sayre syndrome due to cardiac-specific inactivation of mtDNA gene expression (52) and cardiac respiratory chain dysfunction (53). The main function of mitochondria in the cardiac muscle is ATP synthesis via the OXPHOS system. Reducing equivalents, such as the reduced form of nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH\(_2\)) generated by the tricarboxylic acid (TCA) cycle following substrate oxidation (fatty acids or glucose), are used by the respiratory chain to produce an electrochemical gradient across the mitochondrial membrane [mitochondrial membrane potential (ΔΨm)] that drives ATP synthesis. In the adult myocardium, although both fatty acids and glucose are utilized, fatty acids are preferentially oxidized, supplying approximately 70% of total ATP (54, 97). In the failing heart, oxidation of carbohydrate substrates (glucose and lactate) is impaired and fatty acid oxidation (FAO) is enhanced (55). Heart failure patients may benefit from increasing oxidation of pyruvate which derives glucose and lactate, by pharmacologically activating pyruvate dehydrogenase (PDH) (56) (see section Mitochondria as a Therapeutic Target for Cardiomyopathy). Conditional KO mice of adenine nucleotide translocator (Ant1) revealed a dramatic proliferation of mitochondria and cardiac hypertrophy. As Ant1 KO also has the metabolic acidosis phenotype and its isolated mitochondria exhibited a severe defect in coupled respiration, it will be a good animal model to study all the biochemical, histological, metabolic and physiological characteristics of mitochondrial myopathy and CM (57). Desmin-related CM is caused by mutations in desmin, α-B-crystallin (CryAB), and other genes (58, 59). In particular an R120G missense mutation in CryAB results in desmin-related CM (60). Although desmin-related CM caused by mutations in desmin is not associated with mitochondria (61), a mouse model of desmin-related CM caused by CryAB\(^{R120G}\) showed that reduced complex I activity with alterations in the MPT pore and mitochondrial membrane potential (ΔΨm) eventually resulted in cardiac cell death, CM, and heart failure (62). Since deficiencies in the cytoskeletal protein dystrophin have been implicated in the pathogenesis of both genetic and acquired forms of CM (63-65), the dystrophin-deficient mdx mouse is considered a good experimental model for CM. In the mdx mouse heart, a marked shift in substrate from fatty acids to carbohydrates associated with enhanced oxygen consumption was observed (66). Overexpression of the LTCC β2a subunit enhanced Ca\(^{2+}\) influx-induced cellular necrosis and induced CM, supporting the concept that necrosis associated with Ca\(^{2+}\) overload can also contribute to loss of cardiomyocytes in heart failure (67). Furazolidone (Fz), a nitrofuran antibacterial, used to establish a turkey model of DCM, with similarities to DCM in human (68), was also used to establish a rat model of DCM (69). The Fz-induced rat model heart showed significant myocardial degeneration and mitochondrial swelling with decreases in mitochondrial membrane potential (ΔΨm) and activities of complex II and IV (69).

Together with small animal models, large animal models are needed to translate discoveries from the basic sciences into clinical applications. The pacing-induced DCM model is obtained by continuous cardiac pacing at a higher frequency than the spontaneous heart rate in dogs, pigs, sheep and monkeys (70, 71). In a pacing-induced canine model of DCM, decreases in the enzymatic activity of complex I were observed (72).

**Increased oxidative stress**

Superoxide dismutase 2 (SOD2, also known as mitochondrial MnSOD) mutant mice developed a neonatal CM, indicating that mitochondrial ROS can cause accumulation of oxidative DNA damage (73). As described in the section Dysfunction of Mitochondrial dynamics and quality control, due to impaired Parkin-mediated mitophagy, Mfn2 KO hearts exhibit accumulation of damaged mitochondria, which produces ROS. Cardiomyocyte-specific expression of mitochondrial-targeted catalase reversed ROS-mediated dysfunction of mitochondrial quality control mechanisms in Mfn2 KO hearts (41). Mutation of the Ant1 gene also increases mitochondrial ROS production (57). The most effective anti-cancer drug, doxorubicin (DOX), has been reported to have cardiotoxicity (74, 75) and thus DOX-induced CM has been considered a good model for studying congestive heart failure induced by anthracycline analogues (76, 77). Various DOX-induced CM animal models have been developed in mouse (78), rabbit (79), and rat (80). The increased superoxide production in pacing-induced canine model of DCM and heart failure suggested that complex I is a potential source of mitochondrial production of ROS in failing hearts (72). All these reports provide important insights into the role of mitochondrial ROS in the pathophysiology of CM.

**MITOCHONDRIA AS A THERAPEUTIC TARGET FOR CARDIOMYOPATHY**

The development of experimental models of mitochondrial heart diseases also provides the opportunity to investigate the efficacy of new mitochondria-targeting drugs and their underlying mechanisms of action. Many studies have targeted bioenergetic dysfunction of mitochondria by adding cofactors, such as coenzyme Q or L-carnitine to therapies for treatment of heart failure associated with CM (81, 82). Coenzyme Q10 (also known as ubiquinone) functions as an antioxidant and its deficiency is associated with CM (83). The coenzyme Q analog idebenone corrects cardiac diastolic dysfunction and im-
proves exercise performance in the mdx mouse model of Duchenne muscular dystrophy (DMD) (84). Although initial trials have shown some benefits in preventing progression of HCM, recent controlled trials reported that idebenone neither decreased left ventricular hypertrophy nor improved cardiac function in patients with Friedreich’s ataxia (FRDA) (81, 85). Long-term administration of L-carnitine for the treatment of HF caused by DCM showed improved survival (86). The mitochondria palmitoyltransferase 1 (CPT-I) inhibitor, perhexilene, corrected energy deficiency caused by diastolic dysfunction and improved exercise capacity in HCM patients, suggesting its function as a metabolic modulator (shifting FAO to glucose oxidation) (87). Another CPT-I inhibitor, oxendicine showed similar effects in dog heart, in which CPT-I inhibition prevents ventricular remodeling (88). Dichloroacetate (DCA) is another potential therapy for CM, by stimulating pyruvate dehydrogenase is stimulated to drive pyruvate to mitochondrial OXPHOS, increasing acetyl-CoA and NADH levels. However, treatment of non-ischemic and ischemic DCM patients with DCA showed inconsistent effects on left ventricular mechanical efficiency and myocardial O₂ consumption (89, 90). L-arginine has also been proposed as a treatment for CM. In patients with mitochondrial CM, L-arginine enhanced aerobic metabolism and myocardial efficiency, independent of its vasodilatation effect (91). Because the primary target of DOX-induced CM is the mitochondria, in which DOX triggers the generation of ROS and lipid peroxidation (76, 77), numerous studies have tested iron-chelating agents [e.g., dexrazoxane (92)], antioxidants [e.g., MnTBAP and ebselen (93)], and the phosphodiesterase 5 inhibitor sildenafil (94) to prevent the mitochondrial dysfunctions in DOX-induced CM.

CONCLUDING REMARKS

Mitochondrial dysfunction is substantially involved in arrhythmogenic cardiac diseases, including inherited and acquired CM. Alterations in mitochondrial morphology, impaired energy production (i.e. ATP synthesis) and enhanced pathologic function (i.e. ROS generation, Ca²⁺ overload and apoptosis) cause cardiomyocyte injury and/or cell death due to malfunction of cellular mechanisms involved in maintaining intracellular Ca²⁺ homeostasis and normal mechanical and electrical functions of heart.

Although interpretations must be made with appropriate caution, i.e. “a man will never be a mouse”, studies of mitochondrial function in cardiac disease using animal models will undoubtedly continue to provide new insights into the mechanisms of cardiac mitochondrial damage and a better understanding of the mitochondrial-mediated injury pathways involved in CM and heart failure. Current pharmacologic strategies have not yet been proven effective, and large randomized controlled trials are needed to establish a link between mitochondria and CM. Cross-disciplinary analysis will hopefully provide unique insights into mitochondrial disorders and optimum translational models with which to challenge our perspectives on human CM and heart failure while also suggesting new therapeutic strategies.

ACKNOWLEDGEMENTS

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2014R1A2A1A11052412).

REFERENCES

1. Walters AM, Porter GA Jr. and Brookes PS (2012) Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res 111, 1222-1236
2. Roger VL, Go AS, Lloyd-Jones DM et al (2012) Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation 125, e2-e220
3. Ambrosio G, Zweier JL, Duling C et al (1993) Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow. J Biol Chem 268, 18332-18341
4. Lucas DT and Szweda LI (1998) Cardiac reperfusion injury: aging, lipid peroxidation, and mitochondrial dysfunction. Proc Natl Acad Sci U S A 95, 510-514
5. Murphy E and Steenbergen C (2008) Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 88, 581-609
6. Brenner C and Moulin M (2012) Physiological roles of the permeability transition pore. Circ Res 111, 1237-1247
7. Kwong JQ and Molkentin JD (2015) Physiological and pathological roles of the mitochondrial permeability transition pore in the heart. Cell Metab 21, 206-214
8. Hutt JM and Kelly DP (2003) Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 115, 547-555
9. Towbin JA and Bowles NE (2002) The failing heart. Nature 415, 227-233
10. Cecchi F, Tomberli B and Olivotto I (2012) Clinical and molecular classification of cardiomyopathies. Glob Cardiol Sci Pract 2012, 4
11. Ozuwa T (1994) Mitochondrial cardiomyopathy. Herz 19, 105-118, 125
12. Stanley WC and Hoppel CL (2000) Mitochondrial dysfunction in heart failure: potential for therapeutic interventions? Cardiovasc Res 45, 805-806
13. Lesniewski EJ, Moghadam S, Tandler B, Kerner J and Hoppel CL (2001) Mitochondrial dysfunction in cardiac disease: ischemia–reperfusion, aging, and heart failure. J Mol Cell Cardiol 33, 1065-1089
14. Ikeda Y and Ross J Jr. (2000) Models of dilated cardiomyopathy in the mouse and the hamster. Curr Opin Cardiol 15, 197-201
15. Benjamin IJ and Schneider MD (2005) Learning from failure: congestive heart failure in the postgenomic age. J Clin Invest 115, 495-499
16. Recchia FA and Lioniatti V (2007) Animal models of dilated cardiomyopathy for translational research. Vet Res
An experimental approach to study the function of mitochondria in cardiomyopathy
Youn Wook Chung and Seok-Min Kang

17. Wallace DC and Fan W (2010) Energetics, epigenetics, mitochondrial genetics. Mitochondrion 10, 12-31
18. Winnik S, Auwers J, Sinclair DA and Matter CM (2015) Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J [Epub ahead of print]
19. Ryu D, Jo YS, Lo Sasso G et al (2014) A SIRT7-dependent acetylation switch of GABPbeta1 controls mitochondrial function. Cell Metab 20, 856-869
20. Roh JJ, Cheong C, Sung YH et al (2014) Perturbation of NCOA6 leads to dilated cardiomyopathy. Cell Rep 8, 991-998
21. Lauritzen KH, Kleppa L, Aronsen JM et al (2015) Impaired dynamics and function of mitochondria caused by mtDNA toxicity leads to heart failure. Am J Physiol Heart Circ Physiol 309, H434-449
22. Sligh JE, Levy SE, Waymire KG et al (2000) Maternal differences between subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle: effects of procedural technique. J Mol Cell Cardiol 21, 1029-1036
23. Baba A, Yoshikawa T, Fukuda Y et al (2004) Autoantibodies against M2-muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. Eur Heart J 25, 1108-1115
24. Fu LX, Magnusson Y, Bergh CH et al (1995) Functional epitope analysis of the second extracellular loop of the human heart muscarinic acetylcholine receptor. J Mol Cell Cardiol 27, 427-436
25. Zhang S, He Z, Wang J et al (2015) Mitochondrial dysfunction is essential for cardiac-expressed death domain targets in atrial fibrillation in patients with dilated cardiomyopathy. Eur J Heart Fail 17, 1329-1338
26. Chen L, Liu T, Tran A et al (2012) OPA1 mutation and NCOA6 leads to dilated cardiomyopathy. Cell Rep 8, 725-730
27. Syed F, Odley A, Hahn HS et al (2004) Physiological growth synergizes with pathological genes in experimental cardiomyopathy. Circ Res 95, 1200-1206
28. Palmer JW, Tandler B and Hoppel CL (1977) Biochemical properties of subsarcomemal and interfibrillar mitochondria isolated from rat cardiac muscle. J Biol Chem 252, 8731-8739
29. Shin G, Sugiyama M, Shoji T, Kagiyama A, Sato H and Ogura R (1989) Detection of mitochondrial membrane damages in myocardial ischemia with ESR spin labeling technique. J Mol Cell Cardiol 21, 8731-8739
30. Delbridge LM, Mellor KM, Taylor DJ and Gottlieb RA (2015) Myocardial autophagic energy stress responses—macroautophagy, mitophagy, and glycophagy. Am J Physiol Heart Circ Physiol 308, H194-202
31. Hoppel CL, Tandler B, Parland W, Turkaly JS and Albers LD (1982) Hamster cardiomyopathy. A defect in oxidative phosphorylation in the cardiac interfibrillar mitochondria. J Biol Chem 257, 1540-1548
32. D’Angelo DD, Sakata Y, Lorenz JN et al (1997) Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A 94, 8121-8126
33. Sakata Y, Hoit BD, Liggett SB, Walsh RA and Dorn GW 2nd (1998) Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice. Circulation 97, 1488-1495
34. Yussman MG, Toyokawa T, Odley A et al (2002) Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med 8, 725-730
35. Gray MW, Burger G and Lang BF (1999) Mitochondria from rat cardiac muscle: effects of procedural differences between subsarcolemmal and interfibrillar mitochondria. J Biol Chem 252, 1540-1548
36. Shirihai OS, Song M and Dorn GW 2nd (2015) How mitochondrial fission and fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured fibroblasts. Cell Metab 21, 273-285
37. Ryu D, Jo YS, Lo Sasso G et al (2014) A SIRT7-dependent acetylation switch of GABPbeta1 controls mitochondrial function. Cell Metab 20, 856-869
38. Palmer JW, Tandler B and Hoppel CL (1977) Biochemical properties of subsarcomemal and interfibrillar mitochondria isolated from rat cardiac muscle: effects of procedural technique. J Mol Cell Cardiol 21, 1029-1036
39. Sligh JE, Levy SE, Waymire KG et al (2000) Maternal differences between subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle: effects of procedural technique. J Mol Cell Cardiol 21, 1029-1036
An experimental approach to study the function of mitochondria in cardiomyopathy
Youn Wook Chung and Seok-Min Kang

51. Fosslien E (2003) Review: Mitochondrial medicine—cardiomyopathy caused by defective oxidative phosphorylation. Ann Clin Lab Sci 33, 371-395
52. Wang J, Wilhelmsson H, Graff C et al (1999) Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. Nat Genet 21, 133-137
53. Li H, Wang J, Wilhelmsson H et al (2000) Genetic modification of survival in tissue-specific knockout mice with mitochondrial cardiomyopathy. Proc Natl Acad Sci U S A 97, 3467-3472
54. Wisneski JA, Gertz EW, Neese RA and Mayr M (1987) Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest 79, 359-366
55. Stanley WC and Chandler MP (2002) Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev 7, 115-130
56. Stanley WC, Lopaschuk GD, Hall JL and McCormack JG (1997) Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 33, 243-257
57. Graham BH, Waymire KG, Cottrell B, Trouble IA, MacGregor GR and Wallace DC (1997) A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet 16, 226-234
58. Engel AG (1999) Myofibrillar myopathy. Ann Neurol 46, 681-683
59. Paulin D, Huet A, Khanamyrian L and Xue Z (2004) Desminopathies in muscle disease. J Pathol 204, 418-427
60. Vicart P, Caron A, Guicheney P et al (1998) A missense mutation in the desmin-related myopathy. Nat Genet 20, 92-95
61. Wang X, Osinska H, Dorn GW 2nd et al (2001) Mouse model of desmin-related cardiomyopathy. Circulation 103, 2402-2407
62. Maloyan A, Sanbe A, Osinska H et al (2005) Mitochondrial dysfunction and apoptosis underlie the pathogenic process in alpha-B-crystallin desmin-related cardiomyopathy. Circulation 112, 3461-3464
63. Badorff C, Lee GH, Lamphere BJ et al (1999) Entero viral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5, 320-326
64. Feng J, Yan J, Buzin CH, Towbin JA and Sommer SS (2002) Mutations in the dystrophin gene are associated with sporadic dilated cardiomyopathy. Mol Genet Metab 77, 119-126
65. Vatta M, Stetson SJ, Perez-Verdia A et al (2002) Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet 359, 936-941
66. Khairallah M, Khairallah R, Young ME, Dyck JR, Petrof BJ and Des Rosiers C (2007) Metabolic and signalling alterations in dystrophin-deficient hearts precede overt cardiomyopathy. J Mol Cell Cardiol 43, 119-129
67. Nakayama H, Chen X, Baines CP et al (2007) Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 117, 2431-2444
68. Hajjar RJ, Liao R, Young JB, Fuleihan F, Glass MG and Gwathmey JK (1993) Pathophysiological and biochemical characterisation of an avian model of dilated cardiomyopathy: comparison to findings in human dilated cardiomyopathy. Cardiovasc Res 27, 2212-2221
69. Zhang M, Wei J, Shen H et al (2013) Calreticulin-STAT3 signaling pathway modulates mitochondrial function in a rat model of furazolidone-induced dilated cardiomyopathy. PLoS One 8, e66779
70. Armstrong PW, Stoppes TP, Ford SE and de Bold AJ (1986) Rapid ventricular pacing in the dog: pathophysiological studies of heart failure. Circulation 74, 1075-1084
71. Spinale FG, Hendrick DA, Crawford FA, Smith AC, Hamada Y and Carabello BA (1990) Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am J Physiol 259, H218-229
72. Ide T, Tsutsui H, Kinugawa S et al (1999) Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85, 357-363
73. Melov S, Coskun P, Patel M et al (1999) Mitochondrial disease in superoxide dismutase 2 mutant mice. Proc Natl Acad Sci U S A 96, 846-851
74. Lefrak EA, Pitka J, Rosenheim S and Gottlieb JA (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32, 302-314
75. Gilladoga AC, Manuel C, Tan CT, Wolliner N, Stemberg SS and Murphy ML (1976) The cardiotoxicity of adriamycin and daunomycin in children. Cancer 37, 1070-1078
76. Takenuma H and Fujiwara H (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49, 330-352
77. Sawyer DB (2013) Anthracyclines and heart failure. N Engl J Med 368, 1154-1156
78. van der Vijgh WJ, van Velzen D, van der Poort JS et al (1988) Morphometric study of myocardial changes during doxorubicin-induced cardiomyopathy in mice. Eur J Cardiovasc Dis 24, 1603-1608
79. Shenasa H, Calderone A, Vermeulen M et al (1990) Chronic doxorubicin induced cardiomyopathy in rabbits: mechanical, intracellular action potential, and beta adrenergic characteristics of the failing myocardium. Cardiovasc Res 24, 591-604
80. Lebrecht D, Setzer B, Ketselsen UP, Haberstroh J and Walker UA (2003) Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 108, 2423-2429
81. Kerr DS (2010) Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab 99, 246-255
82. Gurlek A, Tutar E, Akcil E et al (2000) The effects of L-car nitine treatment on left ventricular function and erythrocyte superoxide dismutase activity in patients with ischemic cardiomyopathy. Eur J Heart Fail 2, 189-193
83. Singh RB, Niaz MA, Rastogi V and Rastogi SS (1998) Coenzyme Q in cardiovascular disease. J Assoc Physicians India 46, 299-306
84. Buyse GM, Van der Mieren G, Erb M et al (2009) Long-
An experimental approach to study the function of mitochondria in cardiomyopathy
Youn Woock Chung and Seok-Min Kang

85. Lagedrost SJ, Sutton MS, Cohen MS et al (2011) Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J 161, 639-645 e631
86. Rizos I (2000) Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 139, S120-123
87. Abozguia K, Elliott P, McKenna W et al (2010) Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122, 1562-1569
88. Lionetti V, Linke A, Chandler MP et al (2005) Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovasc Res 66, 454-461
89. Bersin RM, Wolfe C, Kwasman M et al (1994) Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 23, 1617-1624
90. Lewis JF, DaCosta M, Wargowich T and Stacpoole P (1998) Effects of dichloroacetate in patients with congestive heart failure. Clin Cardiol 21, 888-892
91. Arakawa K, Kudo T, Ikawa M et al (2010) Abnormal myocardial energy-production state in mitochondrial cardiomyopathy and acute response to L-arginine infusion. C-11 acetate kinetics revealed by positron emission tomography. Circ J 74, 2702-2711
92. Lebrecht D, Geist A, Ketelsen UP, Haberstroh J, Setzer B and Walker UA (2007) Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol 151, 771-778
93. Konorev EA, Kennedy MC and Kalyanaraman B (1999) Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. Arch Biochem Biophys 368, 421-428
94. Fisher PW, Salloum F, Das A, Hyder H and Kukreja RC (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111, 1601-1610
95. Wagner JA, Weisman HF, Snowman AM, Reynolds IJ, Weisfeldt ML and Snyder SH (1989) Alterations in calcium antagonist receptors and sodium-calcium exchange in cardiomyopathic hamster tissues. Circ Res 65, 205-214
96. Li Y, Huang TT, Carlson EJ et al (1995) Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 11, 376-381
97. Shipp JC, Opie LH and Challoner D (1961) Fatty acid and glucose metabolism in the perfused heart. Nature 189, 1018-1019